Trial Profile

An Expanded Access Protocol of Intravenous Trehalose Injection 90.5 mg/mL Treatment of Patients With Amyotrophic Lateral Sclerosis

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trehalose (Primary)
Indications Amyotrophic lateral sclerosis
Focus Expanded access; Therapeutic Use
Sponsors Seelos Therapeutics

Most Recent Events

22 Apr 2024 Status changed from suspended to completed.
04 Apr 2023 According to a Seelos Therapeutics media release, the first patient has been dosed in this Expanded Access Program (EAP).
13 Feb 2023 According to a Seelos Therapeutics media release, this trial is expected to begin late in the first quarter of2023 that is fully funded by a grant from the NINDS under the ACT for ALS.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com